GEN

Rare Bleeding Disorder, HHT, Treated Successfully with Cancer Drug in Clinical Trial

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...
EurekAlert!

Clinical trial successfully repurposes cancer drug for hereditary bleeding disorder

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
News Medical

Multiple myeloma drug shows efficacy in treating rare bleeding disorder

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...
Morningstar

Diagonal’s First-in-Class Clustering Antibody, DIAG723, Receives Orphan Drug Designation (ODD) from U.S. FDA and an ODD Positive Opinion from EMA for Treatment of Hereditary ...

‍HHT is a rare disease that affects more than 150,000 people in the U.S. and EU, and for which there are currently no approved therapies. In HHT, loss-of-function point mutations in members of the TGF ...
WGN Radio

Diagonal Therapeutics Initiates Natural History Study of Adults Living with Hereditary Hemorrhagic Telangiectasia (HHT), a Rare Bleeding Disorder with No Approved Treatments

Study conducted in partnership with Cure HHT will inform future clinical trials and treatment options for people living with HHT Company recently progressed DIAG723 into IND-enabling studies for HHT ...
FierceBiotech

Vaderis scores win against rare blood vessel disorder as trial shows its drug reduces nosebleeds

Vaderis Therapeutics’ goal to develop the first drug aimed specifically at a certain rare blood vessel disorder came one step closer today with the news that the therapy is safe and reduced nosebleeds ...